Author:
Maison-Blanche Pierre,Dakhil Shaker,Baron Ari,Rottey Sylvie,Millard Fred,Daugaard Gedske,Machiels Jean-Pascal,Conkright William,Sharma Sunil,Soetekouw Patricia M. M. B.,Yachnin Jeffrey,Sengeløv Lisa,Van Veldhuizen Peter,Agarwala Sanjiv S.,Sémiond Dorothée,Chadjaa Mustapha,Shen Liji,Wade James L.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference26 articles.
1. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154
2. Shah RR (2005) Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf 28:115–125
3. Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N (2009) Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157:827–836
4. Valentin JP (2010) Reducing QT liability and proarrhythmic risk in drug discovery and development. Br J Pharmacol 159:5–11
5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2005) Guidance for industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073153.pdf . Accessed 1 Apr 2014
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献